These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28034844)

  • 21. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Laske C
    N Engl J Med; 2014 Apr; 370(15):1459. PubMed ID: 24716688
    [No Abstract]   [Full Text] [Related]  

  • 22. [Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].
    Peters O
    Dtsch Med Wochenschr; 2014 Mar; 139(10):468. PubMed ID: 24570189
    [No Abstract]   [Full Text] [Related]  

  • 23. Amyloid Cascade into Clarity.
    Weitz TM; Town T
    Immunity; 2016 Oct; 45(4):717-718. PubMed ID: 27760336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 25. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 26. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's drug update. Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.
    Harv Mens Health Watch; 2013 Jan; 17(6):6-7. PubMed ID: 23819191
    [No Abstract]   [Full Text] [Related]  

  • 29. A "keto-enol" plaque buster mechanism to diminish Alzheimer's β-Amyloid burden.
    Zoltán O; László P; Éva K; Béla V
    Biochem Biophys Res Commun; 2020 Oct; 532(1):82-87. PubMed ID: 32828536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
    Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
    Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Doody RS; Farlow M; Aisen PS;
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24716687
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease.
    Lansbury PT
    Curr Opin Chem Biol; 1997 Aug; 1(2):260-7. PubMed ID: 9667848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
    Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
    Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical success against Alzheimer's disease with an old drug.
    LaFerla FM
    N Engl J Med; 2012 Aug; 367(6):570-2. PubMed ID: 22873540
    [No Abstract]   [Full Text] [Related]  

  • 39. Alzheimer's disease: expedition into the unknown.
    The Lancet
    Lancet; 2016 Dec; 388(10061):2713. PubMed ID: 27924761
    [No Abstract]   [Full Text] [Related]  

  • 40. Antibody drugs for Alzheimer's show glimmers of promise.
    Reardon S
    Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.